RECA/OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS
RECA/OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS
批准号:
2421808
负责人:
ROBERT A DUBIN
金额:
$8.9万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-09-15 至 1998-04-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The ability to alter specifically the genome of cells holds great promise
for gene therapy, treatment of certain infectious diseases, and the
creation of animal models of human genetic disease. We will develop a
general method of targeted mutagenesis capable of introducing a specific,
single basepair alteration into any gene in a living cell using the E.
coli RecA protein and a synthetic oligonucleotide. The E. coli RecA
protein plays an essential role in bacterial homologous recombination and
DNA repair and promotes pairing and strand invasion between RecA-coated,
single-stranded DNA and homologous duplex DNA in vitro. Here, a modified
RecA (engineered to contain a nuclear localization signal) is complexed
with a short mutagenic oligonucleotide that contains a single base
difference from that found in the target cellular gene. This nucleoprotein
complex is introduced into cultured cells using liposomes, where RecA
protects the mutagenic oligonucleotide from degradation, directs it toward
the nucleus, promotes the searching and pairing of the oligonucleotide
with its homologous gene, and initiates strand exchange. Mismatch
distortion within the heteroduplex stimulates DNA repair and gene
conversion, resulting in stable introduction into the cellular gene of the
sequence alteration present on the oligonucleotide. Phase I will examine
RecA/oligonucleotide-dependent targeted repair of an extrachromosomal
mutant reporter gene in human and primate cultured cells. The efficiency
of gene repair will be monitored qualitatively and quantitatively.
PROPOSED COMMERCIAL APPLICATION:
This research is directed towards developing a general method of
introducing specific genetic alterations into cells. Potential
applications include in vivo and ex vivo human gene therapy, therapeutic
intervention for certain cancers and infectious diseases, alteration of
cells for structural/functional protein analysis, and development of
animal models for human genetic disease.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Aldolase C/zebrin gene regulation by prolactin during pregnancy and lactation.
妊娠和哺乳期间催乳素对醛缩酶 C/zebrin 基因的调节。
DOI:
10.1385/endo:20:1-2:91
发表时间:
2003
期刊:
Endocrine
影响因子:
3.7
作者:
[Matsuda,Manabu, Lockefeer,JasonA, Horseman,NelsonD]
通讯作者:
Horseman,NelsonD
Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells.
在乳腺上皮细胞中通过 Jak2 和 Stat5a 诱导 NF-kappaB 配体的受体激活剂。
DOI:
10.1074/jbc.m308545200
发表时间:
2003
期刊:
The Journal of biological chemistry
影响因子:
--
作者:
[Srivastava,Sunil, Matsuda,Manabu, Hou,Zhaoyuan, Bailey,JasonP, Kitazawa,Riko, Herbst,MatthewP, Horseman,NelsonD]
通讯作者:
Horseman,NelsonD
EFFICIENT NUCLEAR DELIVERY VECTOR FOR MACROMOLECULES
-
批准号:6021317
-
项目类别:
-
资助金额:$9.31万
-
财政年份:1999
-
负责人:ROBERT A DUBIN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
asr基因调控酸诱导的Escherichia coli O157:H7形成VBNC状态的机制研究
-
批准号:32302245
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:潘寒姁
-
依托单位:
小肠中Escherichia coli分泌细菌毒素诱导肠屏障损伤及细菌易位在炎症性肠病中的机制研究
-
批准号:82371775
-
项目类别:面上项目
-
资助金额:46万元
-
批准年份:2023
-
负责人:朱慧媛
-
依托单位:
基于Escherichia coli O157:H7亚致死态细胞探究超高压与原儿茶酸协同杀菌机制
-
批准号:31871817
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2018
-
负责人:孙爱东
-
依托单位:
肠肝轴:从临床患者分离的肠道致病菌株Escherichia coli NF73-1对非酒精性脂肪性肝病的作用及机制研究
-
批准号:81873549
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2018
-
负责人:刘玉兰
-
依托单位:
高压二氧化碳诱导Escherichia coli O157:H7形成VBNC状态的分子机制
-
批准号:31571933
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2015
-
负责人:廖小军
-
依托单位:
超高压诱导牛肉中Escherichia coli O157:H7亚致死损伤及其修复研究
-
批准号:31371861
-
项目类别:面上项目
-
资助金额:15.0万元
-
批准年份:2013
-
负责人:江芸
-
依托单位:
高压二氧化碳诱导Escherichia coli O157:H7形成VBNC状态的机制
-
批准号:31371845
-
项目类别:面上项目
-
资助金额:15.0万元
-
批准年份:2013
-
负责人:廖小军
-
依托单位:
高密度二氧化碳致死Escherichia coli的相关蛋白质确证及其结构变化研究
-
批准号:31171774
-
项目类别:面上项目
-
资助金额:66.0万元
-
批准年份:2011
-
负责人:张德权
-
依托单位: